News
One Dose of Ad5-nCoV , a #COVID19 Vaccine Developed in #China, is 57.5% ... - Latest Tweet by IANS India
The latest Tweet by IANS India states, 'One dose of Ad5-nCoV , a #COVID19 vaccine developed in #China, is 57.5% effective against symptomatic Covid-19 and 91.7% effective against severe Covid-19 disease beginning 28 days post-vaccination, finds a new study.'
One dose of Ad5-nCoV (Convidecia), a #COVID19 vaccine developed in #China, is 57.5% effective against symptomatic Covid-19 and 91.7% effective against severe Covid-19 disease beginning 28 days post-vaccination, finds a new study. pic.twitter.com/uezqJxauJ2— IANS Tweets (@ians_india) December 25, 2021
(The above story first appeared on LatestLY on Dec 25, 2021 02:22 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
